Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics

Advanced Delivery. True Empty/Partial/Full Analytics. Greater Confidence for Gene Therapy Developers. Agreement brings together Solid's POLARIS-101™ (AAV-SLB101) next-generation capsid and NanoMosaic's FDA AMT-designated Tessie™ platform to provide gene therapy developers enhanced access...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.